Atogepant FDA Approval Status
Last updated by Judith Stewart, BPharm on Nov 19, 2019.
Atogepant is a novel, highly potent, orally-administered CGRP receptor antagonist in development for the prevention of migraine.
Development Timeline for atogepant
|Mar 30, 2021||U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine|
|Jul 29, 2020||AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.